# Biosynthesis and genome mining strategies for purine-derived N-nucleoside antibiotics

## TL;DR

This paper reviews strategies for discovering new nucleoside antibiotics by analyzing their biosynthesis and genetic patterns.

## Contribution

The paper provides a framework for genome mining of purine-derived nucleoside antibiotics using conserved biosynthetic enzymes.

## Key findings

- Purine-derived N-NAs show diverse enzymatic modifications leading to varied pharmacological profiles.
- Core enzyme probes can guide genome-based discovery of new nucleoside antibiotics.
- Structure–Activity relationships in subclasses like pentostatin and angustmycin can aid rational drug design.

## Abstract

The rise of antibiotic resistance underscores the urgent need for new antimicrobial agents. Nucleoside antibiotics are a structurally diverse class with broad biological activities, among which purine-derived N-nucleoside antibiotics (N-NAs) are of particular interest as their purine-linked frameworks enable diverse enzymatic modifications that yield compounds with distinct pharmacological profiles.

This review summarizes the bioactivity and biosynthetic logic of representative purine-derived N-NAs, including pentostatin-type compounds, angustmycins, and deazapurine analogues, to provide insights into the genome-based discovery of related natural products.

By outlining conserved enzymes and genetic features within known BGCs, we illustrate how core enzyme probes can be used for genome-guided mining of putative clusters. This approach emphasizes both the opportunities and challenges in predicting novel N-NA producers from genomic data.

Understanding the biosynthesis and genetic organization of N-NAs not only sheds light on their structural diversity but also provides a framework for genome mining. Specific subclasses such as pentostatin-, angustmycin-, and deazapurine-type compounds exhibit Structure–Activity relationships that could guide the rational design and genome-based discovery of new nucleoside antibiotics.